PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
Status:
Recruiting
Trial end date:
2024-11-15
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept phase 2 clinical trial to investigate the effect of the
phytoestrogenic supplement PhytoSERM on vasomotor symptoms and other symptoms associated with
the menopausal transition, and on blood-based biomarkers in peri- and postmenopausal women.
After the screening period, participants will be randomized to PhytoSERM 50 mg pills
(administered orally, once per day) or matching placebo, 1:1 allocation, for a period of 12
weeks. After 12 weeks, all participants in the placebo group will be crossed-over to receive
PhytoSERM pills for the remainder of the study (open-label phase).